SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid a mixed earnings report and its announcement to cease Model S and X production to focus on Optimus robot manufacturing, leading to widespread community discussion about the company's identity shift toward AI and robotics.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares is surging to fresh all-time highs, fueled by escalating geopolitical tensions and concerns over the U.S. dollar's stability. The community is actively discussing its role as a key safe-haven asset, alongside speculation of a significant short squeeze in the market.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amidst a disputed Reuters report suggesting the U.S. is moving away from guaranteed price floors for critical minerals, which the community largely views as a market manipulation "hit piece." Many investors are buying the dip, asserting that CRML's robust heavy rare earth project and pre-sold concentrate make it less reliant on such policies, while eagerly anticipating an upcoming critical minerals summit.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following a strong earnings beat and optimistic guidance that has ignited bullish sentiment, with the community actively debating the company's massive AI capital expenditure as both a driver for future growth and a point of caution.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana (CVNA) is trending following a Gotham City Research report alleging significant accounting irregularities and a heavy reliance on undisclosed related-party transactions with DriveTime, sparking a sharp stock decline and heated community debate over the validity of these fraud claims versus a potential short-seller-induced panic.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending after its earnings report showed beats on top and bottom lines, but the stock is falling due to investor concerns over slowing Azure cloud growth, substantial capital expenditures for AI, and pressured margins, leading the community to question the immediate return on its aggressive AI investments including OpenAI.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

A widely contested report about the U.S. government potentially ending critical mineral price floors is driving a sector-wide sell-off for United States Antimony Corp, yet the community largely dismisses this as market manipulation and views the ensuing dip as a buying opportunity. Bullish sentiment is further fueled by UAMY's unique role as a domestic antimony producer for defense, recent processing advancements, and a significant production halt at a major Chinese antimony plant.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is trending ahead of its upcoming earnings report, with bulls anticipating a significant beat driven by strong commercial growth and AI platform adoption, while bears cite extreme overvaluation and ongoing ethical concerns surrounding its government contracts, particularly with ICE, as reasons for caution.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as the Federal Reserve's decision to hold rates, alongside recent dissent for cuts, sparks community debate over monetary policy independence and the impact of geopolitical actions, such as proposed tariffs related to Greenland, which are causing some investors to reconsider demand for U.S. long-duration debt.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is a major talking point following its strong Q4 earnings beat and raised guidance, which paradoxically led to a significant stock decline, sparking community debate about the market's seemingly irrational reaction to the software leader's expanded AI integrations and substantial share repurchase authorization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html">announced</a> its intent to wind down operations and explore asset sales.iTeos said it decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value.The Board of Directors now intends to focus on leveraging the company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the company’s intellectual property and assets.iTeos ended the first quarter of 2025 with cash and investments of $624.3 million. Last month, the firm had said that it expects its cash balance to provide a runway through 2027.However, earlier this month, iTeos decided to <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">terminate</a> its collaboration with British pharmaceutical major GSK Plc for the development of experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy, and the companies subsequently decided to terminate the program and end the collaboration.iTeos CEO Michel Detheux had said the company is “truly disappointed” by the trial results and is taking “immediate steps” to preserve capital. &nbsp;On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_11_05_44_AM_png_7ce0e324ab.webp" alt="ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="67"><figcaption>ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user expressed optimism about the company’s decision to halt operations.<stembedurl>https://stocktwits.com/BullDriven/message/616043049</stembedurl><a href="https://stocktwits.com/symbol/ITOS">ITOS stock </a>is up approximately 29% this year but down by more than 40% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-gets-rmat-designation-for-prostate-cancer-therapy/ch0om35Rbs0">Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 

Equity

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to terminate its collaboration with British pharmaceutical major GSK Plc for the development of its experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy. Hence, the two companies have decided to end the collaboration and terminate the program.iTeos <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-reports-topline-interim-results-galaxies-lung-201-study">also</a> ended new enrollment for a phase 3 trial of the combination.GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for the appropriate management of currently enrolled patients, iTeos said.iTeos CEO Michel Detheux said the company is “truly disappointed” by the trial results. The firm is taking “immediate steps” to preserve capital and maximise shareholder value and has engaged TD Cowen to advise on the process.“...given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,” Detheux said, while adding that the company has a strong balance sheet to enable it to pursue opportunities.On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_9_51_08_AM_png_54cf65be0f.webp" alt="ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ITOS">ITOS stock</a> is up by about 5% this year but has declined by about 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/vehicle-prices-rose-in-april-after-trump-tariffs/chi8mIbRbZg">Cadillac, Tesla, GMC Vehicles Get More Expensive In April After Trump Tariffs, Shows Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

ITOS
ITeos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ITOS News

ITOSITeos Therapeutics Inc